VRTX Vertex Pharmaceuticals
Wonderful monopoly-like moat in CF, but priced for pipeline bets that are far less certain than the core franchise.
The business
Vertex dominates cystic fibrosis treatment with a near-monopoly of modulator therapies (Trikafta/Kaftrio and successors) covering ~90%+ of eligible genotypes, generating high-margin, recurring specialty-pharma revenue. It's now diversifying into non-opioid pain (suzetrigine/Journavx), gene-edited cell therapy for sickle cell/beta-thalassemia (Casgevy with CRISPR), type 1 diabetes cell therapy, and APOL1 kidney disease.
Quality gate · 86/100
Moat & management
| Moat | wide moat |
| Source | regulatory |
| Trajectory | stable |
| Management | excellent |
CF franchise is protected by patents into the mid-2030s, deep clinical/regulatory data moats, and high patient switching costs once stabilized on therapy — no competitor has cracked this niche in over a decade. Durability is stable rather than widening because CF patient penetration is near-saturated, so the core moat is mature even though pipeline diversification (pain, gene therapy) opens new, less-proven ones.
Near-zero net debt, FCF conversion of 0.91, shrinking share count via disciplined buybacks, and R&D reinvestment with a solid (if imperfect) hit rate — Alpine and CRISPR partnerships show sensible bolt-on capital allocation rather than empire-building.
Owner-earnings inputs
| Owner earnings (TTM) | 3.71B |
| Owner-earnings yield | 3.0% |
| Free-cash-flow yield | 3.0% |
| Growth used (normalized) | 9.0% |
| Market-implied growth (reverse DCF) | 14.5% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 9.0% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 3.91B | 9.0% | 3.59B |
| 2 | 4.25B | 8.6% | 3.58B |
| 3 | 4.59B | 8.1% | 3.55B |
| 4 | 4.95B | 7.7% | 3.51B |
| 5 | 5.31B | 7.3% | 3.45B |
| 6 | 5.67B | 6.9% | 3.38B |
| 7 | 6.04B | 6.4% | 3.30B |
| 8 | 6.40B | 6.0% | 3.21B |
| 9 | 6.76B | 5.6% | 3.11B |
| 10 | 7.10B | 5.1% | 3.00B |
| 11 | 7.44B | 4.7% | 2.88B |
| 12 | 7.76B | 4.3% | 2.76B |
| 13 | 8.06B | 3.9% | 2.63B |
| 14 | 8.33B | 3.4% | 2.49B |
| 15 | 8.58B | 3.0% | 2.36B |
Key risks
- CF franchise growth is decelerating as eligible-patient penetration approaches ceiling, leaving next-decade growth dependent on unproven new launches
- Journavx/pain and Casgevy adoption ramps are slow and payer/formulary-dependent — commercial uptake could disappoint versus expectations baked into price
- Patent cliffs on core CF therapies loom in the mid-2030s, a real terminal-value risk just past the underwriting horizon
- Binary clinical/regulatory risk inherent to pharma pipelines (trial failures, safety signals, pricing/reimbursement pressure)
Catalysts
- Continued share gains and international reimbursement expansion for CF portfolio in younger age cohorts
- Journavx ramp as a non-opioid alternative in acute and eventually chronic pain, a potentially very large market
- Casgevy and diabetes cell-therapy (zimislecel) scaling as manufacturing/infrastructure hurdles ease
Recent news
score · 8 articles
- Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued?
- Vertex Pharmaceuticals (VRTX) Stock Looks Like A Bargain At This Price
- Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
- AbCellera, Vertex partner on next-gen T-cell engagers
- Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
- Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
- Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
- Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Net cash 3.1B credited to value (interest stripped from owner earnings to avoid double-counting). · Price pays for ~14%/yr owner-earnings growth over 15y (reverse DCF); model credits 9%. · Rich vs our conservative value, but a quality business is not a short — stance is WAIT for a better price, not sell.